Darapladib is an oral, investigational, highly potent, and selective Lp-PLA2 inhibitor that has been demonstrated to reduce atherosclerosis in a diabetic and hypercholesterolemic porcine model of accelerated coronary atherosclerosis [13] as well as in ApoE-deficient mice [14]. This evidence concerns the gene PLA2G7 and atherosclerosis.